| Name | Title | Contact Details |
|---|
OneZero Solutions is a cybersecurity, information technology, and information assurance company that specializes in providing premier services within the cybersecurity arena. They were founded in 2017 by Al Sowers, a medically retired member of the Uni...
Productivity Automation that Drives Revenue 30% of a knowledge worker’s time is wasted on non-billable tasks CF7239F0-9AAC-4185-A5EB-6BAFBBE16515 Save Hours on Admin Process TimeAutomate repetitive admin tasks that require cognition to drive efficiency...
Banyan Technology delivers a fully integrated and tailored SaaS-based logistics management platform that connects carriers, shippers, 3PLs and supply chain partners, empowering each user with unprecedented intelligence and actionability. As North America`s leading provider of live carrier and API connectivity for transportation management, Banyan Technology provides real-time intel, actionable insights and instant access to opportunities that drive greater operational efficiencies and create significant value for your bottom line. Our LTL aggregator platform, LIVE Connect, provides instant two-way freight shipping information between shippers and their preferred carriers, including: rating, tendering. tracking and document retrieval. Additionally, our lightning-fast API connection, Intelligent Freight Pricing Suite, allows carriers to maximize their relationships with shippers and 3PLs in two ways: Capacity Optimizer™, which allows pricing agility, enabling carriers to adjust rates to attract more desired shipments or raise rates to control freight flows and increase profitability – all while maintaining contract obligations, and Insights™, which provides essential relative pricing data analysis tools to guide your pricing decisions. Banyan Technology also has more full-service LTL carrier connections than any other provider, connecting shippers/3PLs to the carriers that move more than 95% of all LTL freight in the country.
IPM.ai transforms RWD via AI to uncover the ideal patient population so pharmaceutical can commercialize therapies for specialty and rare disease